Table 2. Outcomes and risk thresholds for quality of bowel preparation and use of colonoscopic modalities (advanced imaging techniques) in IBD.

	Smallmean (SD)	Moderatemean (SD)	Largemean (SD)
Quality of bowel preparation
Preparation quality (using validated scores)	6.7% (3)	12.7% (7.7)	23.5% (14.7)
Adenoma/polyp detection rates	3.9% (2.8)	7.2% (4.4)	12.3% (7.5)
Patient tolerability to take/complete the bowel prep	5.6% (2.9)	11.2% (7.4)	18.8% (11.6)
Patients with serious adverse events only	2.4% (1.3)	4% (2.8)	6.4% (5.2)
Caecal intubation rates	3.5% (1.5)	6.9% (3.6)	10.8% (5.4)
Patient acceptability/willingness to repeat	4.9% (2.8)	10.7% (7.2)	17.4% (11.4)
Patient withdrawals due to adverse events	3.6% (2.5)	5.1% (3.2)	9.3% (8)
Colonoscopic modalities (advanced imaging techniques) in IBD
Detection of dysplastic lesions (as per Vienna classification: indefinite for dysplasia, low‐grade dysplasia, high‐grade dysplasia or invasive neoplasia at histological examination)	3.3% (2.4)	5.8% (3)	11.2% (7.1)
Yield of any dysplasia from targeted biopsies (per patient)	3.4% (2.9)	6.7% (5)	10.9% (7.5)
Yield of any dysplasia from random biopsies (per patient)	3.5% (4.8)	6.2% (7.2)	10% (10.2)
Patients with serious adverse events	2.6% (2.5)	5.1% (4.7)	8.4% (7.1)
Detection of any lesions in patients (neoplastic lesions detected, that is, dysplastic+serrated and/or non-neoplastic-endoscopic findings with no evidence of dysplasia or invasive neoplasia at histology)	4.1% (2.2)	7.9% (4.4)	15.1% (12.4)
Patient acceptability/willingness to repeat	3.7% (2.4)	6.1% (4.9)	9.6% (7.5)
Patient withdrawals due to adverse events	3.1% (2.5)	5.5% (4.8)	8.6% (7.4)

IBDinflammatory bowel disease